Introduction {#section5-2042018820930902}
============

The prevalence of obesity continues to surge globally and constitutes a major source of morbidity, mortality, and low quality of life.^[@bibr1-2042018820930902]^ Obesity is a systemic disease caused by abnormal accumulation of body fat, which triggers diverse chronic complications, including diabetes, angiopathy, and cardiovascular diseases.^[@bibr2-2042018820930902],[@bibr3-2042018820930902]^ Despite significant awareness efforts, obesity and its complications continue to increase, reaching epidemic levels.^[@bibr4-2042018820930902]^

Obesity-mediated chronic low-grade inflammation is called meta-inflammation, and is characterized by increased plasma levels of systemic inflammatory C-reactive protein (CRP), adipokines including interleukin (IL)-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), IL-6, IL-8 (or CXCL8), IL-12, and the hormone leptin.^[@bibr5-2042018820930902][@bibr6-2042018820930902]--[@bibr7-2042018820930902]^ Immune cells in obese adipose tissue (AT) exacerbate local inflammation by producing inflammatory factors, including chemokines and cytokines. Chemokines (CCL2, CCL3, CCL5, CCL7, CCL8, CCL19, CCL11) as well as chemokine receptors (CCR1, CCR2, CCR3, CCR5) have been associated with obesity and metabolic inflammation.^[@bibr8-2042018820930902][@bibr9-2042018820930902]--[@bibr10-2042018820930902]^ AT is a plastic and dynamic endocrine organ. Besides functioning as the primary location for triacylglycerol deposit, AT produces hormones and secretes cytokines, chemokines, and angiogenic factors.^[@bibr11-2042018820930902]^ The plasticity of AT is linked closely to angiogenesis, which is crucial for its physiological expansion or regression by a mechanism that has yet to be delineated.^[@bibr12-2042018820930902]^ Aberrant AT vascularization, however, induces pathological inflammatory and metabolic dysfunctions that are often detected in obese individuals.^[@bibr13-2042018820930902],[@bibr14-2042018820930902]^

CXCLs (CXCL9, CXCL10, and CXCL11) play a key role in many inflammatory diseases.^[@bibr15-2042018820930902]^ Like other chemokines, these factors regulate cell trafficking of various types of leukocytes into inflammatory sites and aggravate inflammation.^[@bibr16-2042018820930902]^ Abnormal angiogenesis, inflammation, and immune cell infiltration usually characterize actively expanding AT during obesity.^[@bibr17-2042018820930902]^ CXCL9, CXCL10, and CXCL11 are involved in the recruitment, migration, and activation of immune cells.^[@bibr18-2042018820930902],[@bibr19-2042018820930902]^ AT expression levels of these chemokines and their association with other inflammatory markers are not well defined during obesity. Therefore, in this study, we show, for the first time, that the simultaneous increased expression of CXCL9, CXCL10, and CXCL11 in ATs of overweight/obese individuals correlates with inflammatory and metabolic markers in the same population.

Materials and methods {#section6-2042018820930902}
=====================

Study population and anthropometric measurements {#section7-2042018820930902}
------------------------------------------------

The study cohort comprised 59 non-diabetic individuals from both genders who were enrolled at a gymnasium facility or from exercise studies at Dasman Diabetes Institute. Using the standard formula for the body mass index (BMI) = body weight (kg)/height^2^ (m^2^), the cohort was divided into 10 lean (BMI \< 25 kg/m^2^), 20 overweight (25 ⩽ BMI \< 30 kg/m^2^), and 29 obese (BMI ⩾ 30 kg/m^2^) individuals. For each category, the sample size was dependent on the sample availability and each participant's decision to be engaged in the research study. Exclusion criteria included diseases of the lung, heart, kidney, or liver; hematologic disorders; pregnancy; immune dysfunction; diabetes (types 1 and 2); or malignancy, as previously described.^[@bibr20-2042018820930902]^ Written informed consent was obtained from all study participants following the ethical guidelines of the Declaration of Helsinki and approved by the ethics committee at Dasman Diabetes Institute, Kuwait (grant numbers RA 2010-003; RA AM 2016-007). Heights and weights were measured using calibrated, portable electronic weighing scales and portable, inflexible height-measuring bars; waist circumferences were measured using constant-tension tape. Whole-body compositions including percent body fat, soft lean mass, and total body water were measured using an IOI 353 Body Composition Analyzer (Jawon Medical, Seoul, South Korea). Biochemical and physical characteristics of the participants are summarized in [Table 1](#table1-2042018820930902){ref-type="table"}.

###### 

Demographic and clinical characteristics of study population.

![](10.1177_2042018820930902-table1)

  Phenotype       Lean            Overweight      Obese            Lean *versus* overweight   Lean *versus* obese
  --------------- --------------- --------------- ---------------- -------------------------- ---------------------
  Age (years)     42.7 ± 8.17     43.05 ± 11.19   45.41 ± 13.15    0.931                      0.546
  Weight (kg)     62.93 ± 11.90   79.49 ± 9.66    93.84 ± 13.77    \<0.0001                   \<0.0001
  Height (cm)     1.66 ± 0.12     1.67 ± 0.11     1.64 ± 0.10      0.701                      0.659
  BMI (kg/m^2^)   22.82 ± 2.35    28.30 ± 1.17    34.87 ± 3.30     \<0.0001                   \<0.0001
  Waist (cm)      81.33 ± 12.44   95.19 ± 8.81    106.74 ± 12.86   0.003                      \<0.0001
  Body fat (%)    28.37 ± 6.27    32.52 ± 4.87    39.56 ± 4.25     0.073                      \<0.0001
  TGL (mmol/l)    0.63 ± 0.24     1.21 ± 0.62     1.35 ± 0.86      0.001                      \<0.0001
  FBG (mmol/l)    4.97 ± 0.64     5.24 ± 0.67     5.37 ± 0.77      0.292                      0.151
  HbA1c (%)       5.66 ± 0.46     5.51 ± 0.44     5.69 ± 0.65      0.388                      0.884
  Chol (mmol/l)   5.3 ± 1.11      4.97 ± 0.71     5.03 ± 1.14      0.323                      0.521
  HDL (mmol/l)    1.69 ± 0.51     1.26 ± 0.29     1.16 ± 0.27      0.006                      0.009
  LDL (mmol/l)    3.31 ± 0.93     3.18 ± 0.65     3.28 ± 1.01      0.659                      0.933
  WBC             5.57 ± 1.60     6.25 ± 1.52     6.58 ± 1.93      0.283                      0.161

BMI, body mass index, Chol, cholesterol; FBG, fasting blood glucose; LDL, low-density lipoprotein; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; SD, standard deviation; TGL, plasma triglycerides.

Collection of subcutaneous AT {#section8-2042018820930902}
-----------------------------

Human AT samples (approximately 0.5 g) were collected *via* abdominal subcutaneous fat pad biopsy lateral to the umbilicus using standard surgical procedure as described previously.^[@bibr9-2042018820930902]^ Briefly, the periumbilical area was sterilized by alcohol swab and then locally anesthetized using 2% lidocaine (2 ml). Fat tissue was collected through a small superficial skin incision (0.5 cm). After removal, biopsy tissue was further incised into smaller pieces of approximately 50--100 mg, rinsed with cold phosphate-buffered saline and preserved in RNAlater and stored at −80°C until use.^[@bibr21-2042018820930902]^

Measurement of metabolic inflammatory markers {#section9-2042018820930902}
---------------------------------------------

Peripheral blood was collected from overnight-fasted individuals and analyzed for fasting blood glucose (FBG), lipid profile, glycated hemoglobin (HbA1c), fasting insulin, and CRP. FBG and lipid profiles \[plasma triglycerides (TGL), high-density lipoprotein (HDL), and cholesterol (Chol)\] were measured using Siemens Dimension RXL chemistry analyzer (Diamond Diagnostics, Holliston, MA, USA). HbA1c was measured using a Variant™ device (Bio-Rad, Hercules, CA, USA). Homeostatic model assessment (HOMA-IR) as a measure of insulin resistance was calculated from basal (fasting) glucose and insulin concentrations using the following formula: HOMA-IR = fasting insulin (μU/l) × FBG (nmol/l)/22.5. Plasma high-sensitivity CRP levels were measured by enzyme-linked *immunosorbent* assay (ELISA; BioVendor, Ashville, NC, USA). All assays were performed following instructions of the manufacturers.

RNA extraction, cDNA synthesis, and RT-qPCR reactions {#section10-2042018820930902}
-----------------------------------------------------

Total RNA was extracted from AT using RNeasy kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. The first-strand cDNA was synthesized from 0.5 µg RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Waltham, MA, USA). Real-time RT-qPCR was performed as described^[@bibr9-2042018820930902]^; cDNA samples (50 ng) were amplified using TaqMan® Gene Expression Master Mix (Applied Biosystems) and gene-specific 20 × TaqMan gene expression assays (Applied Biosystems) containing forward and reverse primers (listed in [Supplemental Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2042018820930902)) and target-specific TaqMan® MGB probes labeled with FAM dye at the 5′-end and NFQ-MGB at the 3′-end of the probe using 7500 Fast Real-Time PCR System (Applied Biosystems). Each cycle involved denaturation (15 s at 95°C), annealing/extension (1 min at 60°C) after uracil-DNA glycosylases (UDG, 2 min at 50°C) and AmpliTaq gold enzyme (10 min at 95°C) activation. Relative gene expression to the lean AT control was calculated using the comparative cycles to threshold (C~T~) method as previously described.^[@bibr22-2042018820930902]^ Results were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and means ± standard error of the mean (SEM) are shown expressed as fold changes in expression relative to controls as indicated.^[@bibr23-2042018820930902]^

Statistical analysis {#section11-2042018820930902}
--------------------

Statistical analysis was performed using GraphPad Prism software (GraphPad, La Jolla, CA, USA) and SPSS for Windows version 19.01 (IBM SPSS Inc., Chicago, IL, USA). Unless otherwise indicated, data were shown as mean ± standard deviation (SD) values. Unpaired Student's *t* test was used to compare means between groups. Correlation and stepwise multiple regression analysis were performed to determine associations between different variables. For all analyses, a *p* value \< 0.05 was considered significant. Standard multiple linear regression by the Enter method was used; variables that significantly correlated with CXCL11 were selected as predictor variables and were entered simultaneously to generate the model. The *F*-test was used to assess whether the set of entered independent variables collectively predicts the dependent variable. *R*-squared was used to determine how much variance in the dependent variable can be accounted for by the set of independent variables. The *t* test, (*p* value) and beta coefficients (β-value) were used to determine the significance and the magnitude of prediction for each independent variable, respectively.

Results {#section12-2042018820930902}
=======

Demographic and clinical characteristics of the study population {#section13-2042018820930902}
----------------------------------------------------------------

The characteristics of the 59 individuals included in this study are detailed in [Table 1](#table1-2042018820930902){ref-type="table"}. All participants were within the age range of 34--58 years old, with no significant differences in height. Relative to the lean individuals, overweight and obese individuals showed a statistically significant increase in BMI, waist circumference, total body fat, and plasma TGL. Mean values for total plasma Chol and low-density lipoprotein (LDL) levels were comparable between all three groups. HDL measurements were significantly higher in lean individuals ([Table 1](#table1-2042018820930902){ref-type="table"}).

CXCL gene expression is associated with obesity {#section14-2042018820930902}
-----------------------------------------------

We studied gene expression at the transcriptional (mRNA) level in subcutaneous AT. At a basal level, the expression of CXCL9 and CXCL10 were comparable, whereas CXCL11 showed 2.5-fold higher expression levels ([Figure 1A--C](#fig1-2042018820930902){ref-type="fig"}). Relative to lean individuals, AT RT-qPCR analysis revealed a marginal surge of CXCL transcripts in overweight participants and a statistically significant increase in its levels in obese subjects ([Figure 1](#fig1-2042018820930902){ref-type="fig"}).

![The expression levels of CXCLs in AT; RT-qPCR analysis for CXCLs RNA isolated from AT from lean, overweight and obese individuals. A CXCL9, B CXCL10, **C** CXCL11.\
AT, adipose tissue; CXCL, angiostatic chemokines; RT-qPCR, quantitative reverse transcriptase polymerase chain reaction.](10.1177_2042018820930902-fig1){#fig1-2042018820930902}

In biomedical parameters, CXCL9 and CXCL10 expression exhibited a positive association with the BMI (*r* ⩾ 0.269, *p *\< 0.05; [Table 2](#table2-2042018820930902){ref-type="table"}). By contrast, CXCL11 transcripts positively correlated with several parameters including BMI (*r* = 0.286, *p *= 0.029), FBG (*r* = 0.292, *p *= 0.026), body fat percentage (*r* = 0.402, *p *= 0.004), and plasma CRP (*r* = 0.356, *p *= 0.024) ([Table 2](#table2-2042018820930902){ref-type="table"}). No correlation between the CXCL family members and the lipid profile (plasma TGL, HDL, LDL, and Chol) was noted. Interestingly, CXCL9 and CXCL10 gene expressions were not correlated to each other, yet both were positively correlated with that of CXCL11 ([Table 3](#table3-2042018820930902){ref-type="table"}).

###### 

Correlation of CXCLs expression levels in non-diabetic overweight and obese subjects with various clinical and biochemical markers.

![](10.1177_2042018820930902-table2)

  Metabolic markers   CXCL9                                                             CXCL10   CXCL11                                                                                                                                      
  ------------------- ----------------------------------------------------------------- -------- ----------------------------------------------------------------- ------- ----------------------------------------------------------------- -------
  Age                 0.012                                                             0.929    0.05                                                              0.71    0.131                                                             0.324
  Weight              −0.072                                                            0.584    0.077                                                             0.566   0.152                                                             0.25
  Height              −0.091                                                            0.488    −0.121                                                            0.367   −0.048                                                            0.716
  BMI                 **0.339[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.012    **0.281[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.037   **0.290[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.03
  PBF                 0.082                                                             0.562    0.193                                                             0.175   **0.286[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.042
  CHOL                0.152                                                             0.248    0.09                                                              0.502   0.057                                                             0.669
  HDL                 −0.075                                                            0.57     −0.195                                                            0.142   −0.121                                                            0.363
  LDL                 0.201                                                             0.123    0.168                                                             0.208   0.107                                                             0.42
  TGL                 −0.005                                                            0.972    0.011                                                             0.937   0.004                                                             0.975
  GLU                 0.141                                                             0.282    0.142                                                             0.287   **0.292[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.026
  HbA1c               0.009                                                             0.944    0.135                                                             0.318   0.189                                                             0.154
  Insulin             −0.051                                                            0.742    −0.051                                                            0.747   0.208                                                             0.181
  HOMA-IR             −0.039                                                            0.799    −0.026                                                            0.872   **0.395[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.009
  CRP                 0.272                                                             0.086    0.168                                                             0.299   **0.349[\*](#table-fn3-2042018820930902){ref-type="table-fn"}**   0.025

BMI, body mass index, CHOL, cholesterol; CXCLs, angiostatic chemokines; FBG, fasting blood glucose; CRP, C-reactive protein; GLU, glucose; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment; LDL, low-density lipoprotein; PBF, percent body fat; SD, standard deviation; TGL, plasma triglycerides.

Bold values with statistically significant correlations as indicated with the prospective *p*-value column.

###### 

Correlation of CXCLs with various cytokines/chemokines in non-diabetic overweight and obese subjects.

![](10.1177_2042018820930902-table3)

  Inflammatory markers   CXCL9                                                               CXCL10   CXCL11                                                                                                                                            
  ---------------------- ------------------------------------------------------------------- -------- -------------------------------------------------------------------- -------- ------------------------------------------------------------------- --------
  CXCL9                  1                                                                            0.235                                                                0.075    **0.285[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**     0.029
  CXCL10                 0.235                                                               0.075    1                                                                             **0.739[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  CXCL11                 **0.285[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**     0.029    **0.739[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   1                                                                   
  Interleukins                                                                                                                                                                                                                                          
  IL-1β                  0.03                                                                0.845    **0.656[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   **0.516[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  IL-2                   0.044                                                               0.745    0.229                                                                0.089    **0.426[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.001
  IL-5                   0.002                                                               0.99     −0.056                                                               0.691    0.023                                                               0.87
  IL-6                   0.008                                                               0.956    **0.504[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   **0.470[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  IL-8                   −0.056                                                              0.7      0.121                                                                0.414    0.146                                                               0.315
  IL-12A                 0.034                                                               0.826    0.199                                                                0.211    0.285                                                               0.068
  IL-13                  0.054                                                               0.702    −0.1                                                                 0.486    −0.022                                                              0.878
  TNF-α                  0.1                                                                 0.472    **0.427** [\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}   0.002    **0.450[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.001
  CC chemokine ligands                                                                                                                                                                                                                                  
  CCL2                   0.132                                                               0.327    **0.546[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   **0.537[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  CCL3                   −0.004                                                              0.979    0.097                                                                0.489    0.215                                                               0.118
  CCL5                   0.121                                                               0.417    0.264                                                                0.076    **0.468[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.001
  CCL8                   0.229                                                               0.107    **0.721** [\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}   0.0001   **0.501[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  CCL7                   −0.04                                                               0.77     0.125                                                                0.368    0.174                                                               0.204
  CCL11                  0.214                                                               0.116    **0.393[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.004    **0.325[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**     0.015
  CCL15                  0.211                                                               0.108    −0.03                                                                0.822    −0.106                                                              0.428
  CCL18                  0.114                                                               0.395    0.238                                                                0.075    **0.373[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.004
  CCL19                  0.233                                                               0.082    **0.272[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**      0.045    **0.489[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  CCL20                  0.051                                                               0.704    **0.516[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   **0.391[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.003
  CCR2                   0.255                                                               0.068    **0.582[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.0001   **0.589[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  CCR5                   **0.268[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**     0.04     **0.398[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**    0.002    **0.562[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.0001
  Macrophage markers                                                                                                                                                                                                                                    
  CD86                   **0.397[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.002    **0.337[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**      0.012    **0.362[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.007
  CD163                  0.227                                                               0.083    **0.309[\*](#table-fn5-2042018820930902){ref-type="table-fn"}**      0.02     **0.413[\*\*](#table-fn5-2042018820930902){ref-type="table-fn"}**   0.001

CXCLs, angiostatic chemokines; IL, interleukin; TNF-α, tumor necrosis factor alpha.

Bold values with statistically significant correlations as indicated with the prospective *p*-value column.

In AT, increased CXCL gene expression relates to inflammatory signatures {#section15-2042018820930902}
------------------------------------------------------------------------

We next correlated the levels of CXCL transcripts to those of inflammatory regulatory markers in AT. As shown in [Table 3](#table3-2042018820930902){ref-type="table"}, our data indicate that, in obese subjects, CXCL10 expression was associated positively with pro-inflammatory markers including IL-1β and IL-6 (*r* ⩾ 0.504; *p *= 0.0001). CXCL11 showed correlations with a broader number of interleukins: IL-1β (*r* = 0.516; *p *= 0.0001), IL-2 (*r* = 0.426; *p *= 0.001) and IL-6 (*r* = 0.470; *p *= 0.0001). No correlation between CXCL9 and the studied interleukins was observed ([Table 3](#table3-2042018820930902){ref-type="table"}). Moreover, no statistically significant correlation was observed between CXCLs and the B-cell maturation and differentiation markers IL-5 or IL-13, or with the T*h*1 cell marker IL-12A, suggesting that these CXCLs are not associated with anti-inflammatory markers. TNF-α transcription levels were correlated with those of CXCL10 and CXCL11 (*r* = 0.427, *p *= 0.002; and *r* = 0.450, *p *= 0.001; respectively; [Table 3](#table3-2042018820930902){ref-type="table"}).

Interestingly, CXCL expression levels were positively associated with several of the closely related CC motif chemokines observed in macrophages and lymphocytes that mediate obesity-induced chronic inflammation, including CCL2, CCL5, CCL8, CCR2, and CCR5 (0.325 ⩽ *r* ⩽0.589; *p* \< 0.01). Like the interleukins, the CXCLs associated differentially with CCL family members. All three factors correlated positively with CCR5, whereas CXCL10 and CXCL11 were closely correlated with other cytokines ([Table 3](#table3-2042018820930902){ref-type="table"}). Parameters that showed significant associations with CXCL11 were further studied. As shown in [Table 4](#table4-2042018820930902){ref-type="table"}, multiple regression analysis indicated that IL-6, CCL19, and CCR5 were independently associated with CXCL11.

###### 

Multi linear regression: non-diabetic subjects, dependent variable: CXCL11.

![](10.1177_2042018820930902-table4)

  ANOVA (Sig) R2 = 0.56           
  ----------------------- ------- -------
  IL-6                    0.182   0.001
  CCL19                   0.612   0.004
  CCR5                    0.534   0.001
  TLR3                    1.198   0.002

IL, interleukin; TLR, toll-like receptor.

Association between AT CXCL expression and toll-like receptors {#section16-2042018820930902}
--------------------------------------------------------------

We next investigated any prospective correlations between CXCL expression and the toll-like receptors (TLRs). Indeed, we observed a statistically significant positive correlation between the three CXCL transcripts and that of TLR2 and TLR7 (*r* ⩾ 0.313; *p* \< 0.01). Excluding TLR9, CXCL11 expression was significantly associated with all other TLRs as well (TLR2, TLR3, TLR4, TLR7, TLR8, TLR10; *r* ⩾ 0.311; *p ⩽* 0.03; [Table 5](#table5-2042018820930902){ref-type="table"}).

###### 

Correlation of CXCL11 with TLR signaling pathways in non-diabetic overweight and obese subjects.

![](10.1177_2042018820930902-table5)

  TLRs      CXCL9                                                               CXCL10   CXCL11                                                                                                                                          
  --------- ------------------------------------------------------------------- -------- ------------------------------------------------------------------- ------- ------------------------------------------------------------------- -------
  TLR2      **0.594[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0        **0.438[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.002   **0.445[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.001
  TLR3      0.191                                                               0.17     0.25                                                                0.071   **0.343[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.013
  TLR4      0.273                                                               0.057    0.276                                                               0.055   **0.311[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.031
  TLR7      **0.365[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.004    **0.313[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.017   **0.438[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.001
  TLR8      **0.343[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.009    0.238                                                               0.081   **0.437[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.001
  TLR9      0.157                                                               0.236    −0.007                                                              0.96    0.207                                                               0.119
  TLR10     0.076                                                               0.575    **0.297[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.029   **0.337[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.012
  MyD88     **0.395[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.002    **0.322[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.015   **0.339[\*\*](#table-fn8-2042018820930902){ref-type="table-fn"}**   0.009
  IRF3      0.132                                                               0.372    0.063                                                               0.678   0.113                                                               0.45
  IRF5      0.217                                                               0.109    0.243                                                               0.077   **0.279[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.039
  NF-*κ*B   0.178                                                               0.175    0.154                                                               0.248   **0.283[\*](#table-fn8-2042018820930902){ref-type="table-fn"}**     0.03

IL, interleukin; IRF, interferon regulatory factor; NF-κB, nuclear factor kappa B.

Bold values with statistically significant correlations as indicated with the prospective *p*-value column.

TLRs exert their cellular effects through canonical signaling pathways mediated by MyD88 and non-canonical signaling mediated by the interferon regulatory factor (IRF) family members. Our data analysis showed positive correlations with these downstream effectors of TLR signaling. Expression levels of the three CXCLs and MyD88 were found to correlate positively (*r* ⩾ 0.322; *p *\< 0.01). No correlation was observed between CXCLs and the MyD88-independent signaling molecule IRF3. In addition, CXCL11 expression was correlated positively with that of IRF5 (*r* = 0.279, *p* = 0.04) and NF-κB (*r* = 0.283, *p* = 0.03) ([Table 5](#table5-2042018820930902){ref-type="table"}).

Association between AT CXCL expression and M1-M2 macrophage transition {#section17-2042018820930902}
----------------------------------------------------------------------

Positive correlation with the TLRs suggested a prospective association with macrophage markers. Our data revealed a positive correlation between CXCL transcripts and the M1 macrophage protein CD86 (*r* ⩾ 0.337; *p *= 0.01). CXCL10 and CXCL11 were associated positively with the M2 macrophage marker CD163 (*r* = 0.309; *p *= 0.02) ([Table 3](#table3-2042018820930902){ref-type="table"}).

Discussion {#section18-2042018820930902}
==========

AT is a lipid depot and an active endocrine organ secreting a variety of adipokines and chemokines.^[@bibr24-2042018820930902]^ Accumulative data suggest that AT dysfunction, inflammation, and inadequate vascularization causes obesity and associated complications.^[@bibr25-2042018820930902],[@bibr26-2042018820930902]^ Angiogenesis is crucial for maintaining normal AT metabolic function and for providing expanding AT with oxygen and nutrients. Insufficient neovascularization causes hypoxia, which then increases inflammation and metabolic dysfunction. CXCLs (CXCL9, CXCL10, and CXCL11; angiostatic chemokines) are involved in the recruitment, migration, and activation of immune cells in inflammatory diseases. Therefore, understanding the role of AT CXCLs in metabolic inflammation may be fundamental to prevent AT abnormalities in obese individuals.

We observed a significant increase in the gene expression of CXCLs in subcutaneous AT from obese subjects relative to that of lean individuals, which positively correlate with BMI, body fat percentage, and CRPs, suggesting a potential association between obesity and metabolic alteration. Similarly, Deiuliis *et al*. reported elevated transcripts of the other angiostatic proteins, CXCR3 and CXCL10, in omental AT from obese patients compared with corresponding tissue from lean subjects.^[@bibr27-2042018820930902]^ Comparing subcutaneous *versus* visceral AT from morbidly obese patients, Hueso *et al*. observed a higher gene expression of CXCR3, CXCL10, and CXCL11 in visceral AT, which is associated with a reduced neovascularization.^[@bibr28-2042018820930902]^ Therefore, impaired angiogenesis is most likely associated with differential expression of the angiostatic chemokines.

Chemokines coordinate leukocyte trafficking to inflammatory sites. In obese individuals, the upregulation of CXCLs was correlated with pro-inflammatory mediators IL-1β, IL-2, IL-6, CCL2, CCL8, CCL20, and TNF-α, but not with anti-inflammatory factors. These pro-inflammatory intermediaries have been implicated in the pathogenesis of various inflammatory disorders including atherosclerosis, coronary heart disease, and diabetes. Using an animal model, the Spiegelman group, in 1993, was the first to associate TNF-α with AT-insulin-resistance-associated obesity.^[@bibr29-2042018820930902]^ Gene expressions of IL-1β, IL-2, and IL-6 are significantly higher in AT isolated from obese individuals, relative to prospective tissues from lean individuals.^[@bibr30-2042018820930902],[@bibr31-2042018820930902]^ Likewise, we recently reported a potent association of CCL19 elevated transcripts with insulin resistance in AT from obese and overweight patients.^[@bibr9-2042018820930902]^ Taken together, these associations between CXCLs and inflammatory markers suggest that, at the onset of obesity, CXCLs and cytokines are produced heavily in inflamed AT, and may subsequently impair insulin sensitivity. The significant correlation of CXCLs with inflammatory factors suggests that they are implicated in the infiltration of immune cells into AT, which substantially contributes to the pathogenesis of obesity. In a similar fashion, CXCL10 is associated with inflammatory factors.^[@bibr32-2042018820930902],[@bibr33-2042018820930902]^ Accordingly, elevated levels of plasma-circulating angiostatic mediators were observed in several inflammation-associated diseases, including chronic ischemic heart disease,^[@bibr34-2042018820930902]^ systematic advanced heart failure,^[@bibr35-2042018820930902],[@bibr36-2042018820930902]^ and hypertension.^[@bibr37-2042018820930902]^

TLRs are well characterized immune receptors that mediate inflammation. Obesity and associated metabolic syndromes are triggered by the activation of TLR2 and TLR4, which is followed by a dynamic cascade leading to the activation of MyD88 and NFκB and the release of pro-inflammatory mediators.^[@bibr38-2042018820930902]^ Several reports from our laboratory show that the AT expression of several TLRs (TLR2, TLR4, TLR8, and TLR10) and downstream signaling molecules (MyD88, IRAK1, IRF3, and NFκB) are higher in obese individuals with or without type 2 diabetes, and these changes were associated directly with BMI, cytokine/chemokine expression, and insulin resistance.^[@bibr21-2042018820930902],[@bibr39-2042018820930902][@bibr40-2042018820930902]--[@bibr41-2042018820930902]^ Interestingly, our data revealed a significant positive correlation between CXCLs and TLRs and their downstream responsive molecules, suggesting a close interaction between the CXC chemokines and the TLR signaling pathways leading to metabolic inflammation.

A notable biological plausibility was observed in the correlations between CXCLs and inflammatory markers, where some markers with comparable Pearson correlation coefficients showed different statistical significance responses, which can be arbitrated to the complexity of the cell--cell crosstalk between AT cells and resident immune cells. Further, we cannot rule out the implication of other non-studied factors that can specifically affect the significance associations between the studied factors. Moreover, the presence of genetic polymorphisms within the studied population at the effector regions of some markers may cause such variations in correlation studies.

In summary, our findings show that AT CXCL10 and CXCL11 expression levels are associated closely with the expression levels of cytokines, chemokines, and TLRs ([Figure 2](#fig2-2042018820930902){ref-type="fig"}), which are characteristics of the development of inflammation and progression of insulin resistance in obese individuals. Our results suggest that CXCL10 and CXCL11 are potential predictor molecules for the onset of obesity, and prospective therapeutic targets to maintain normal glucose homeostasis.

![Schematic representation of CXCLs and their association with metabolic inflammation.\
CXCL, angiostatic chemokines; IL, interleukin; NF-κB, nuclear factor kappa B; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha.](10.1177_2042018820930902-fig2){#fig2-2042018820930902}
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